反应详情

The title compound was prepared following the procedure as described for Example-1 using 2-[(3,5-dichloropyridin-4-yl)amino]-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxylic acid (Intermediate-3, 0.050 g, 0.127 mmol), O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (0.082 g, 0.225 mmol), N-methyl morpholine (0.025 g, 0.247 mmol), DMF (0.5 mL), THF (3.0 mL) and n-hexyl amine (0.026 g, 0.257 mmol) to afford 0.010 g of the desired product. 1HNMR (DMSO-d6): δ 0.86 (s, 3H), 1.23 (s, 3H), 1.28 (m, 8H), 1.49 (s, 3H), 3.01 (s, 2H), 7.32-7.33 (m, 2H), 7.21 (s, 1H), 7.69 (s, 1H), 8.43 (s, 2H), 10.91 (s, 1H), 11.39 (s, 1H); MS [M+H]+: 476.33.

1. customThe title compound was prepared